Exchange: NASDAQ·Updated 04:15 PM EST

ANL News

News
all
press releases
Adlai Nortye (NASDAQ:ANL) Shares Down 8% - Here's What Happened
Adlai Nortye (NASDAQ:ANL) Shares Down 8% - Here's Why...
MarketBeat
Adlai Nortye (NASDAQ:ANL) Shares Down 8% - Here's What Happened
Adlai Nortye (NASDAQ:ANL) Shares Down 8% - Here's Why...
MarketBeat
More News
A $1,000 investment in SLS at the end of 2025 was worth about $5,080 at Tuesday’s close.
Stocktwits
Here is how Adlai Nortye Ltd. Sponsored ADR (ANL) and Thermo Fisher Scientific (TMO) have performed compared to their sector so far this year.
Zacks
The consensus price target hints at an 81.8% upside potential for Adlai Nortye Ltd. Sponsored ADR (ANL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks
Adlai Nortye Ltd. Sponsored ADR (ANL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
Here is how AbCellera Biologics Inc. (ABCL) and Adlai Nortye Ltd. Sponsored ADR (ANL) have performed compared to their sector so far this year.
Zacks
Adlai Nortye Ltd. Sponsored ADR (ANL) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Zacks
Adlai Nortye (NASDAQ:ANL) Stock Price Up 12.3% - Here's Why...
MarketBeat
Here is how ANI Pharmaceuticals (ANIP) and Adlai Nortye Ltd. Sponsored ADR (ANL) have performed compared to their sector so far this year.
Zacks
Adlai Nortye (NASDAQ:ANL) Trading Down 7.3% - Here's Why...
MarketBeat

Advertisement|Remove ads.